INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.

N ColomboA GadducciJ SehouliE RulliJ MäenpääC SessaA MontesPetronella B OttevangerR BergerI VergoteMaurizio D'IncalciC Churruca GalazR ChekerovG B NyvangS RinikerR HerbertsonR FossatiM P Barretina-GinestaM DeryalM R MirzaE BiagioliM IglesiasG FunariM RomeoG TascaB PardoG TognonM J Rubio-PérezA DeCensiUgo De GiorgiP ZolaP Benedetti PaniciM AgliettaV ArcangeliC ZamagniA BolognaA WestermannV Heinzelmann-SchwarzI TsibulakP WimbergerA Povedanull null

Published in: British journal of cancer (2023)

ClinicalTrials.gov, number NCT01379989.

Keyphrases

phase iii
open label
double blind
clinical trial
phase ii
drug delivery
squamous cell carcinoma
study protocol
cancer therapy